ARS Pharmaceuticals (SPRY) Current Leases (2020 - 2025)

ARS Pharmaceuticals has disclosed Current Leases across 6 years of filings, most recently posting $583000.0 for Q3 2025.

• Current Leases for Q3 2025 came in at $583000.0, up 471.57% year-over-year; the trailing twelve-month figure through Sep 2025 was $583000.0 (up 471.57% YoY), and the FY2024 annual result was $42000.0, down 82.28% from the prior year.
• Current Leases came in at $583000.0 for Q3 2025 at ARS Pharmaceuticals, down from $589000.0 in the prior quarter.
• In the past five years, Current Leases ranged from a high of $1.1 million in Q1 2022 to a low of $42000.0 in Q4 2024.
• The 5-year median for Current Leases is $233000.0 (2023), against an average of $435315.8.
• Across the five-year window, Current Leases sank 83.93% in 2021 and jumped 471.57% in 2025, its largest moves.
• ARS Pharmaceuticals' Current Leases stood at $144000.0 in 2021, then jumped by 59.72% to $230000.0 in 2022, then gained by 3.04% to $237000.0 in 2023, then tumbled by 82.28% to $42000.0 in 2024, then soared by 1288.1% to $583000.0 in 2025.
• The last three Current Leases figures came in at $583000.0 (Q3 2025), $589000.0 (Q2 2025), and $73000.0 (Q1 2025), per Business Quant data.